0001178913-26-001984
SEC filingMediWound announced Vericel, its exclusive North America distributor, received a BARDA contract valued at up to $197 million for NexoBrid procurement, manufacturing, and development over ten years.
The BARDA contract award to Vericel represents a major validation of NexoBrid's strategic importance to U.S. government preparedness efforts, potentially unlocking significant revenue for MediWound through its exclusive North American distribution agreement. The $197 million ceiling over ten years includes a $35 million base with $10 million committed in the next 12 months specifically for procuring NexoBrid to stock the U.S. Strategic National Stockpile and establishing a Vendor Managed Inventory system. Optional elements could drive further upside via additional procurement, clinical development for a blast trauma indication, U.S.-based manufacturing validation, and a next-generation room temperature stable formulation. This aligns with prior BARDA support for NexoBrid under contract HHSO100201500035C and positions the product for expanded utility beyond thermal burns. While MediWound relies on Vericel for execution and has not independently verified details, the agreement enhances NexoBrid's commercial footprint in a key market, supporting MediWound's focus on enzymatic tissue repair therapies amid its pipeline advancement with EscharEx for chronic wounds.